Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONTX
Previous Symbol
CUSIPN/A
Phone267-759-3680
Debt
Debt-to-Equity RatioN/A
Current Ratio3.02
Quick Ratio3.02
Price-To-Earnings
Trailing P/E Ratio-0.14
Forward P/E Ratio-1.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$790,000.00
Price / Sales39.19
Cash FlowN/A
Price / CashN/A
Book Value($15.12) per share
Price / Book-0.36
Profitability
EPS (Most Recent Fiscal Year)($40.16)
Net Income$-24,090,000.00
Net Margins-1,746.70%
Return on EquityN/A
Return on Assets-178.28%
Miscellaneous
Employees25
Outstanding Shares5,670,000
Market Cap$33.75 million
OptionableN/A
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
What is Onconova Therapeutics' stock symbol?
Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on the morning of Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics Inc (NASDAQ:ONTX) announced its quarterly earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.20) by $0.15. The biopharmaceutical company earned $0.49 million during the quarter, compared to analysts' expectations of $0.52 million. View Onconova Therapeutics' Earnings History.
When is Onconova Therapeutics' next earnings date?
What price target have analysts set for ONTX?
2 brokers have issued 12-month price targets for Onconova Therapeutics' stock. Their predictions range from $16.00 to $25.00. On average, they anticipate Onconova Therapeutics' share price to reach $20.50 in the next twelve months. This suggests a possible upside of 271.4% from the stock's current price. View Analyst Price Targets for Onconova Therapeutics.
What is the consensus analysts' recommendation for Onconova Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Onconova Therapeutics.
What are Wall Street analysts saying about Onconova Therapeutics stock?
Here are some recent quotes from research analysts about Onconova Therapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are adjusting our price target to $25 from $3, accounting for the 1:15 reverse split and the following factors: (1) adjustment to base year; (2) adjustment to fully diluted share count; and (3) adjusting our projected launch years for IV rigosertib in high-risk MDS from 2020 to 2021, and 2021 to 2022 for the U.S. and ex-U.S. markets, respectively. Our clinical NPV model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (9/27/2018)
- 2. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (8/18/2018)
- 3. Maxim Group analysts commented, "Onconova reported 2Q18 with a net loss of $4.3M and ended the period with $29.5M in cash, runway into 2H19." (8/14/2018)
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a increase in short interest in September. As of September 14th, there was short interest totalling 4,743,686 shares, an increase of 49.6% from the August 31st total of 3,170,961 shares. Based on an average daily trading volume, of 1,824,344 shares, the days-to-cover ratio is presently 2.6 days. Currently, 5.9% of the company's shares are short sold. View Onconova Therapeutics' Current Options Chain.
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Sierra Oncology (SRRA), Emisphere Technologies (EMIS), Innovate Biopharmaceuticals (INNT), Juniper Pharmaceuticals (JNP), Menlo Therapeutics (MNLO), vTv Therapeutics (VTVT), XBiotech (XBIT), Steadymed (STDY), VBI Vaccines (VBIV), TapImmune (MRKR), XOMA (XOMA), Sesen Bio (SESN), Sol Gel Technologies (SLGL), Neos Therapeutics (NEOS) and MOTIF BIO PLC/S (MTFB).
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the folowing people:
- Dr. Ramesh Kumar, Co-Founder, CEO & Director (Age 62)
- Dr. Steven M. Fruchtman, Chief Medical Officer & Pres (Age 67)
- Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 74)
- Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 55)
- Mr. Mark Patrick Guerin, Chief Financial Officer (Age 49)
How do I buy shares of Onconova Therapeutics?
Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Onconova Therapeutics' stock price today?
One share of ONTX stock can currently be purchased for approximately $5.52.
How big of a company is Onconova Therapeutics?
Onconova Therapeutics has a market capitalization of $33.75 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($40.16) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.
What is Onconova Therapeutics' official website?
How can I contact Onconova Therapeutics?
Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]
MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
